Alkermes plc has divulged orexin OX2 receptor agonists reported to be useful for the treatment of cataplexy.

Jazz Pharmaceuticals plc has disclosed macrocyclic orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia, narcolepsy and sleep disorders.

Merck Sharp & Dohme LLC has identified orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia and narcolepsy.

Takeda Pharmaceutical Co. Ltd. has identified orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy.

Orexia Therapeutics Ltd. has identified bicyclic-heterocycle derivatives acting as orexin OX2 receptor agonists. As such, they are reported to be useful for the treatment of narcolepsy, circadian rhythm disorder, genetic disorders, coma, metabolic syndrome, neurodegeneration, osteoporosis and sleep apnea, among others.

Jazz Pharmaceuticals plc has patented sulfonamides acting as orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia, narcolepsy and sleep disorders.

Orexin OX2 receptor agonists have been described in a recent Sumitomo Pharma Co. Ltd. patent as potentially useful for the treatment of hypersomnia, narcolepsy and sleep apnea, among others.

Alkermes Controlled Therapeutics Inc. has patented orexin OX2 receptor (OX2R) agonists reported to be useful for the treatment of cataplexy.

Orexia Therapeutics Ltd. has divulged 2-(3-ethynylbenzyl)-substituted heterocycle derivatives acting as orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy, hypersomnia, insomnia and sleep apnea.